GreenLight Biosciences (NASDAQ:GRNA) and PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Survey
GreenLight Biosciences (NASDAQ:GRNA) and PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Survey
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
GreenLight Biosciences（纳斯达克股票代码：GRNA — 获取评级）和Pharmacyte Biotech（OTCMKTS: PMCBD — 获取评级）都是小型医疗公司，但哪家业务更好？我们将根据两家企业的风险、估值、股息、机构所有权、分析师建议、收益和盈利能力对比这两家企业。
Risk & Volatility
风险与波动性
GreenLight Biosciences has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
GreenLight Biosciences的beta值为1.48，这表明其股价的波动性比标准普尔500指数高48％。相比之下，Pharmacyte Biotech的beta值为0.27，这表明其股价的波动性比标准普尔500指数低73％。
Profitability
盈利能力
This table compares GreenLight Biosciences and PharmaCyte Biotech's net margins, return on equity and return on assets.
该表比较了GreenLight Biosciences和Pharmacyte Biotech的净利润率、股本回报率和资产回报
| Net Margins | Return on Equity | Return on Assets | |
| GreenLight Biosciences | N/A | -195.71% | -45.30% |
| PharmaCyte Biotech | N/A | -49.09% | -43.39% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 绿光生物科学 | 不适用 | -195.71% | -45.30% |
| Pharmacyt | 不适用 | -49.09% | -43.39% |
Valuation and Earnings
估值和收益
This table compares GreenLight Biosciences and PharmaCyte Biotech's gross revenue, earnings per share (EPS) and valuation.
该表比较了GreenLight Biosciences和Parmacyte Biotech的总收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
| PharmaCyte Biotech | N/A | N/A | -$3.83 million | N/A | N/A |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 绿光生物科学 | 不适用 | 不适用 | -1,506 万美元 | 不适用 | 不适用 |
| Pharmacyt | 不适用 | 不适用 | -383 万美元 | 不适用 | 不适用 |
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and PharmaCyte Biotech, as provided by MarketBeat.
这是MarketBeat提供的GreenLight Biosciences和Pharmacyte Biotech最近的评级和目标价格的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| PharmaCyte Biotech | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 绿光生物科学 | 0 | 0 | 3 | 0 | 3.00 |
| Pharmacyt | 0 | 0 | 0 | 0 | 不适用 |
GreenLight Biosciences presently has a consensus target price of $4.50, indicating a potential upside of 798.38%. Given GreenLight Biosciences' higher probable upside, research analysts clearly believe GreenLight Biosciences is more favorable than PharmaCyte Biotech.
GreenLight Biosciences目前的共识目标价为4.50美元，表明潜在的上涨空间为798.38％。鉴于GreenLight Biosciences的上行空间更高，研究分析师显然认为GreenLight Biosciences比Pharmacyte Biotech
Institutional & Insider Ownership
机构所有权和内部所有权
24.4% of GreenLight Biosciences shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 30.3% of GreenLight Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
24.4％的GreenLight Biosciences股票由机构投资者持有。相比之下，Pharmacyte Biotech有0.0％的股票由机构投资者持有。30.3％的GreenLight Biosciences股票由公司内部人士持有。强大的机构所有权表明，大型基金经理、对冲基金和捐赠基金认为一家公司已为长期增长做好了准备。
Summary
摘要
GreenLight Biosciences beats PharmaCyte Biotech on 5 of the 8 factors compared between the two stocks.
与两只股票相比，GreenLight Biosciences在8个因素中的5个方面击败了Pharmacyte B
About GreenLight Biosciences
关于绿光生物科学
(Get Rating)
（获取评分）
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
生物技术公司GreenLight Biosciences Holdings生产和销售用于人类健康和农业应用的核糖核酸（RNA）产品。其用于人类健康的产品包括mRNA疫苗和疗法；以及用于保护蜜蜂和农作物的农用RNA产品。该公司成立于2008年，总部位于马萨诸塞州梅德福。
About PharmaCyte Biotech
关于 Pharmacyte
(Get Rating)
（获取评分）
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.
Pharmacyte Biotech, Inc. 是一家临床阶段的生物技术公司，从事癌症和糖尿病治疗的开发和商业化。它专注于一种名为Cell-in-a-box的基于纤维素的专有活细胞封装技术，该技术将用作开发无法手术的胰腺癌和其他实体癌肿瘤以及糖尿病治疗的平台。该公司成立于1996年10月28日，总部位于加利福尼亚州拉古纳希尔斯。
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收《绿光生物科学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收GreenLight Biosciences及相关公司的最新新闻和分析师评级的简明每日摘要。